BMRN - BIOMARIN PHARMACEUTICAL INC
IEX Last Trade
66.69
-0.115 -0.172%
Share volume: 18,392
Last Updated: Fri 27 Dec 2024 08:29:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$66.80
-0.12
-0.17%
Fundamental analysis
24%
Profitability
14%
Dept financing
14%
Liquidity
45%
Performance
31%
Performance
5 Days
1.13%
1 Month
2.45%
3 Months
-5.04%
6 Months
-19.74%
1 Year
-31.53%
2 Year
-34.40%
Key data
Stock price
$66.69
DAY RANGE
$66.40 - $67.36
52 WEEK RANGE
$62.03 - $99.25
52 WEEK CHANGE
-$30.49
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Jean-Jacques Bienaimé
Region: US
Website: biomarin.com
Employees: 3,080
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biomarin.com
Employees: 3,080
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recent news